Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(145 products)
- Bcr-Abl(102 products)
- EGFR(572 products)
- FAK(72 products)
- FLT(92 products)
- Fibroblast Growth Factor Receptor (FGFR)(170 products)
- JAK(245 products)
- PDGFR(126 products)
- RAAS(86 products)
- Src(78 products)
- Syk(38 products)
- Thrombin(47 products)
- VDA(2 products)
- VEGFR(268 products)
Show 6 more subcategories
Found 1414 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
LB 42708
CAS:Controlled Product<p>Applications LB 42708 is a selective nonpeptidic Farnesyltransferase (FTase) inhibitor.LB42708 suppresses tumor growth and tumor angiogenesis in both xenograft tumor models of Ras-mutated HCT116 cells and its wild-type Caco-2 cells, indicating its potential application in the treatment of both Ras-mutated and wild type tumors.<br>References Kim, C., et. al.: Mol. Pharmacol., 78, 142 (2010)<br></p>Formula:C30H27BrN4O2Color and Shape:NeatMolecular weight:555.46Bucillamine
CAS:<p>Bucillamine (DE019) protects against Ischemia/reperfusion injury in high-risk organ transplants and inhibits the production of VEGF.</p>Formula:C7H13NO3S2Purity:99.47%Color and Shape:SolidMolecular weight:223.31E3330
CAS:<p>E3330 is a potent and selective APE1(Ref-1) inhibitor, which suppressed NF-kappa B DNA-binding activity.</p>Formula:C21H30O6Purity:99.52%Color and Shape:SolidMolecular weight:378.46YLT192
CAS:<p>YLT192 is an orally active and bioavailable VEGFR2 inhibitor. It also has potent antiangiogenic activity and antitumor efficacy.</p>Formula:C21H19N3O4Purity:98%Color and Shape:SolidMolecular weight:377.39TGFBR1-IN-1
CAS:<p>TGFBR1-IN-1 is an inhibitor of ALK5 (IC50 of 10-100 nM).</p>Formula:C23H17N5O2SPurity:98%Color and Shape:SolidMolecular weight:427.48Antiproliferative agent-30
CAS:<p>Antiproliferative agent-30 (Compound 8g) demonstrates broad-spectrum antiproliferative activity, with IC50 values of 0.054 nM, 0.008 nM, and 0.144 nM against</p>Formula:C24H26N4O4Color and Shape:SolidMolecular weight:434.49BTK-IN-24
CAS:<p>BTK-IN-24 is a Bruton's tyrosine kinase (BTK) inhibitor with potential anticancer activity, and it can be used in the study of myeloproliferative disorders.</p>Formula:C26H19F4N5O2Purity:99.61%Color and Shape:SolidMolecular weight:509.46THS-044
CAS:<p>THS-044 (N-[2-Nitro-4-(Trifluoromethyl)phenyl]morpholin-4-Amine) binding stabilizes the HIF2α PAS-B folded state with a kd of 2 μM and regulates HIF2 activity</p>Formula:C11H12F3N3O3Purity:99.89%Color and Shape:SolidMolecular weight:291.23DMPQ dihydrochloride
CAS:<p>PDGFRβ inhibitor</p>Formula:C16H16Cl2N2O2Purity:99.51%Color and Shape:SolidMolecular weight:339.22EGFR-IN-68
CAS:<p>EGFR-IN-68, an EGFR inhibitor, has an IC50 of 0.33 μM and shows significant anticancer effects.</p>Formula:C24H22N2OColor and Shape:SolidMolecular weight:354.44FM19G11
CAS:<p>FM19G11 is an inhibitor of hypoxia inducible factor (HIF) α-subunit (IC50 = 80 nM in hypoxia induced luciferase assay).</p>Formula:C23H17N3O8Purity:99.70%Color and Shape:SolidMolecular weight:463.4BKI-1369
CAS:<p>BKI-1369 is a bumped kinase inhibitor. BKI-1369 increases hERG-inhibitory activity (IC50:1.52 μM).</p>Formula:C23H27N7OColor and Shape:SolidMolecular weight:417.51ACP-5862
CAS:<p>ACP-5862, active metabolite of Acalabrutinib, is a BTK inhibitor with an IC50 of 5.0 nM.</p>Formula:C26H23N7O3Color and Shape:SolidMolecular weight:481.51NSC114126
CAS:<p>NSC114126 is a potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Formula:C22H20O4Color and Shape:SolidMolecular weight:348.39EGFR-IN-50
CAS:<p>EGFR-IN-50, a potent EGFR blocker, hinders L858R mutation; GI50: 8 nM for TEL-EGFR-L858R, 6.03 μM for T790M-L858R; curbs cancer cell growth.</p>Formula:C24H26BrN3O4S2Color and Shape:SolidMolecular weight:564.51FLT3-IN-15
CAS:<p>FLT3-IN-15 is an orally active and potent FLT3 inhibitor, capable of acting on FLT3 (IC50: 0.87 nM) and FLT3/D835Y (IC50: 0.32 nM).</p>Formula:C22H23ClFN5O2Color and Shape:SolidMolecular weight:443.91ALK5-IN-30
CAS:<p>ALK5-IN-30 (EX-07) is a potent inhibitor of ALK with inhibitory effects on ALK5 (IC50< 10 nM) and TGFβ-R1 (IC50< 10 nM).</p>Formula:C24H25FN8Color and Shape:SolidMolecular weight:444.51AG-183
CAS:<p>(Z)-Tyrphostin A51, a Z-isomer of Lanoconazole A51, is a strong PTK inhibitor blocking [3 H]taurine release and tyrosyl phosphorylation.</p>Formula:C13H8N4O3Color and Shape:Brown SolidMolecular weight:268.23NSC81111
CAS:<p>NSC81111 shows anticaner effects which is a potent and orally active inhibitor of EGFR-TK (IC50 = 0.15 nM) [1].</p>Formula:C19H16O4Color and Shape:SolidMolecular weight:308.33Naphazoline
CAS:<p>Naphazoline (Naphcon-a) is a sympathomimetic compound with marked alpha adrenergic activity.</p>Formula:C14H14N2Purity:99.79%Color and Shape:White Crystalline Powder SolidMolecular weight:210.27CJ-2360
CAS:<p>CJ-2360 is a potent ALK inhibitor, effective on wild-type and various mutants, with IC50 values ranging from 2.2 to 8.9 nM, also targeting 468 kinases.</p>Formula:C27H30FN5O2Color and Shape:SolidMolecular weight:475.56SJF620
CAS:<p>SJF620 is a potent degrader of PROTAC BTK(DC50 : 7.9 nM).</p>Formula:C41H44N8O7Purity:98%Color and Shape:SolidMolecular weight:760.84Flonoltinib
CAS:<p>Flonoltinib (JAK2/FLT3-IN-1) is an orally active and efficient JAK2/FLT3 inhibitor with anti-cancer properties.</p>Formula:C25H34FN7OPurity:99.52%Color and Shape:SolidMolecular weight:467.58J-1048
CAS:<p>J-1048, an activin receptor-like kinase 5 (ALK5) inhibitor, effectively suppresses TAA-induced liver fibrosis in mice through specific inhibition of the TGF-β/</p>Formula:C23H17FN6S2Color and Shape:SolidMolecular weight:460.55BTK inhibitor 10
CAS:<p>BTK inhibitor 10, an oral drug from patent WO2018145525, may treat rheumatoid arthritis.</p>Formula:C25H23N5O3Purity:98%Color and Shape:SolidMolecular weight:441.48Peficitinib hydrochloride
CAS:<p>Peficitinib HCl (ASP015K) is an oral JAK inhibitor with IC50s: JAK1 (3.9 nM), JAK2 (5.0 nM), JAK3 (0.7 nM), Tyk2 (4.8 nM).</p>Formula:C18H23ClN4O2Color and Shape:SolidMolecular weight:362.86JAK-IN-20
CAS:<p>JAK-IN-20: potent oral JAK1,2,3 inhibitor with IC50s 7, 5, 14 nM respectively, good pharmacokinetics, anti-inflammatory in vivo.</p>Formula:C28H30FN7O2Color and Shape:SolidMolecular weight:515.58TX-1918
CAS:<p>TX-1918, a tyrphostin, blocks eEF-2K to hinder HepG2, HCT116 cell growth.</p>Formula:C14H12O3Color and Shape:SolidMolecular weight:228.24TK4b
CAS:<p>TK4b, a JAK inhibitor, targets leukemia/lymphoid diseases, with IC50s: 18.42 nM (JAK3) & 19.40 nM (JAK2).</p>Formula:C21H22N2O2Color and Shape:SolidMolecular weight:334.41FLT3/ITD-IN-2
CAS:<p>FLT3/ITD-IN-2: Powerful FLT3/ITD, FLT3D835Y, and FLT3 inhibitor; hinders AML cell growth. IC50s: 0.3-1.0 nM.</p>Formula:C23H26F3N7O2Color and Shape:SolidMolecular weight:489.49KL-1156
CAS:<p>KL-1156 is an NF-κB inhibitor. It is also a lipopolysaccharide (LPS)-induced nitric oxide production inhibitor.</p>Formula:C17H17NO4Purity:98%Color and Shape:SolidMolecular weight:299.32DB07107
CAS:<p>DB07107 is a potent inhibitor of drug resistant T315I mutant Bcr-Abl tyrosine kinase and a potent Akt1 inhibitor (IC50: 360 nM).</p>Formula:C23H22N4OPurity:98%Color and Shape:SolidMolecular weight:370.45PD180970
CAS:<p>PD180970 is an inhibitor of Bcr-Abl with IC50s of 5 nM, 0.8 nM and 50 nM for the autophosphorylation of p210Bcr-Abl, Src and Kit.</p>Formula:C21H15Cl2FN4OPurity:98.67%Color and Shape:SolidMolecular weight:429.27T338C Src-IN-2
CAS:<p>T338C Src-IN-2: Potent c-Src T338C kinase inhibitor; IC50: 317 nM, T338C/V323A: 57 nM, T338C/V323S: 19 nM.</p>Formula:C17H18FN5OPurity:98%Color and Shape:SolidMolecular weight:327.36TK4g
CAS:<p>TK4g, a potent JAK inhibitor, has IC50s of 12.61 nM (JAK2) & 15.80 nM (JAK3); promising for lymphoid diseases & leukemia research.</p>Formula:C19H19N3O4SColor and Shape:SolidMolecular weight:385.44EGFR-IN-67
CAS:<p>EGFR-IN-67 (Compound 7d) is a potent inhibitor of EGFR with anticancer activity (IC 50 = 0.34 μM) [1].</p>Formula:C18H17N3SColor and Shape:SolidMolecular weight:307.41Squarunkin A hydrochloride
CAS:<p>Squarunkin A HCl inhibits UNC119-cargo binding, specifically blocks Src kinase activation, IC50=10 nm.</p>Formula:C25H33ClF3N5O4Color and Shape:SoildMolecular weight:560.02JAK-2/3-IN-2
CAS:<p>JAK-2/3-IN-2 (Compound 3h) is a potent JAK2 & JAK3 inhibitor with IC50s of 23.85 nM (JAK2) & 18.9 nM (JAK3).</p>Formula:C19H19ClN2OSColor and Shape:SolidMolecular weight:358.89JNJ-47117096 hydrochloride
CAS:<p>JNJ-47117096 hydrochloride is potent and selective MELK inhibitor, with an IC50 of 23 nM, also effectively inhibits Flt3, with an IC50 of 18 nM.</p>Formula:C21H23ClN4O2Color and Shape:SolidMolecular weight:398.89c-ABL-IN-2
CAS:<p>C-ABL-IN-2 is a potent c-Abl protein inhibitor, promising for research in cancer and neurodegenerative diseases like ALS and PD.</p>Formula:C21H20N4OColor and Shape:SolidMolecular weight:344.41MS 154N
CAS:<p>MS 154N is a negative control for MS 154, binds WT/L858R EGFR tightly (Kd 3-4.3nM), doesn't trigger mutant EGFR degradation.</p>Formula:C47H56ClFN8O8Color and Shape:SolidMolecular weight:915.45Esuberaprost Sodium
CAS:<p>Famitinib (SHR1020), an oral drug, inhibits c-kit, VEGFR-2, and PDGFRβ (IC50: 2.3/4.7/6.6 nM) and triggers apoptosis in gastric cancer.</p>Formula:C23H27FN4O2Color and Shape:SolidMolecular weight:410.48OD36 hydrochloride
CAS:<p>OD36 hydrochloride (OD-36 hydrochloride) is a potent RIPK2 inhibitor with an IC50 of 5.3 nM.OD36 hydrochloride is a macrocyclic inhibitor that binds efficiently</p>Formula:C16H16Cl2N4O2Purity:99.85%Color and Shape:SolidMolecular weight:367.23TYK2-IN-12
CAS:<p>TYK2-IN-12: selective oral TYK2 inhibitor (Ki: 0.51 nM), blocks IL-12-induced IFNγ; IC50: human 2.7 µM, mouse 7.0 µM, used for psoriasis research.</p>Formula:C24H20F2N4O2Color and Shape:SolidMolecular weight:434.44PDE5-IN-3
CAS:<p>PDE5-IN-3: Inhibits PDE5 (1.57 nM), EGFR (5.827 μM), Wnt pathway (1286.96 ng/mL), induces apoptosis, and has antitumor effects.</p>Formula:C21H14BrN5O2Color and Shape:SolidMolecular weight:448.27PDGFR-IN-1
CAS:<p>PDGFR-IN-1 is a platelet-derived growth factor receptor (PDGFR) inhibitor, strongly inhibiting PDGFRα and PDGFRβ, useful for studying solid tumors.</p>Formula:C25H30N8OPurity:99.13% - 99.49%Color and Shape:SolidMolecular weight:458.56IHMT-TRK-284
CAS:<p>IHMT-TRK-284: Oral type II TRK inhibitor; targets TRKA, TRKB, TRKC (IC50s: 10.5, 0.7, 2.6 nM); selective and anti-tumor effective.</p>Formula:C25H27N7OSColor and Shape:SolidMolecular weight:473.59FGFR3-IN-2
CAS:<p>FGFR3-IN-2 (compound 18b) is a potent and selective FGFR3 inhibitor that inhibits FGFR3 (IC50: 4.1 nM) and VEGFR2 (IC50: 570 nM).</p>Formula:C28H39N9O4SColor and Shape:SolidMolecular weight:597.73CpCDPK1/TgCDPK1-IN-1
CAS:<p>CpCDPK1/TgCDPK1-IN-1 is a inhibitor of CpCDPK1 and TgCDPK1, inhibits Abl and Src, and has antiparasitic activity for the study of Toxoplasma infections.</p>Formula:C18H17N5Purity:99.61%Color and Shape:SolidMolecular weight:303.36AG-370
CAS:<p>AG 370, an indole tyrphostin, functions as a powerful inhibitor of PDGF-induced mitogenesis, demonstrating an IC50 of 20 μM.</p>Formula:C15H9N5Color and Shape:SolidMolecular weight:259.27
